All In Biotech

Drug Trial Radar · NCT07566572

A Study of BGM0504 Tablets in Healthy Chinese Subjects

A Randomized, Open-label, Multiple-dose Phase I Clinical Study to Evaluate the Effect of a High-fat Meal and Different Dosing Conditions on the Pharmacokinetics of BGM0504 Tablets in Healthy Chinese Participants.

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

144

Actual

Start

Mar 26, 2026

Primary completion

Aug 31, 2026

Study completion Aug 31, 2026

Sponsor

Sponsor type
Industry
First posted
May 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A randomized, open-label, multiple-dose study to evaluate the effects of high-fat meals and different administration conditions (including water intake and fasting time) on the pharmacokinetics of BGM0504 tablets at a dose of 20mg in healthy Chinese participants and to assess its safety and tolerability.

Conditions

  • Chinese Healthy Volunteers

Interventions

  • BGM0504 tabletsDrug

    Administered p.o.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetic (PK) endpoint: AUC0-tau,ssTime frame: 4 weeks
  2. PK endpoint:Cmax,ssTime frame: 4 weeks
  3. PK endpoint:t1/2,ssTime frame: 4 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hangzhou First People's Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.